This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
A look at the developing treatment landscape for resistant hypertension, including Baxdrostat and Ocedurenone
Ticker(s): CINC, KBP BiosciencesWho's the expert?
Institution: SWPNA
- more than 120 resistant HTN patients
- familiar with Baxdrostat and Ocedurenone trials
Interview GoalDiscussing the potential of Baxdrostat (CIN-107) in resistant hypertension and the BrigHtn and HALO phase 2 trials and KBP-5074 (Ocedurenone) for CKD patients with resistant hypertension based on the results of the Phase 2b BLOCK-CKD trial
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
